entertainment -WSS

entertainment

author：leisure time 2025-09-28 02:47:37 - browse：33333

Metastatic Melanoma Cells – cancer research coverage from STAT — Metastatic melanoma cells NCI/NIH

Cancer drugs can burn through tumors like a wildfire, killing off the vast majority of malignant cells. But a few stubborn cells often end up surviving, seeding a recurrence of the disease. The prevailing theory behind this drug resistance is built on natural selection: Among the vast and genetically diverse population of cancer cells in a tumor, some have random mutations that help these cells survive an onslaught.

“But this is not the full picture,” said Yogesh Goyal, a cancer researcher at Northwestern University. Goyal and his colleagues at the University of Pennsylvania demonstrated in a series of experiments that cancer cells can survive treatments just by having certain genes turned on, even if they were nearly genetically identical to cancer cells that died but had activated different genes.

“We think this work stands to really change how we think about therapy resistance,” said Arjun Raj, the study’s co-senior author and a bioengineer at the University of Pennsylvania.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Gain of function research would be limited under House proposal

hotspot

WSS

Surge of respiratory disease in China has likely explanation

STAT Summit: The economic case for universal basic health care

Hospitals look to new technology to keep health care workers safe

STAT Readout: Friday, Oct. 20 biotech updates

STAT Summit: Meghan O’Rourke on making chronic illness visible

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

entertainment

knowledge

23andMe had bad news about my health. I wish a person had delivered it

CRISPR pioneers react to Casgevy, first gene

Anesthesiologist group: stop taking Ozempic before surgery

Hospitals look to new technology to keep health care workers safe

Walensky prepares to leave CDC — and Congress — behind

STAT Readout Newsletter: Biotech news today

DIEP, the 'gold standard' of breast reconstruction, is under threat

STAT Readout Newsletter: Biotech news today

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Gain of function research would be limited under House proposal

hotspot

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Astellas still sees hope in its gene therapy after four deaths

Is there really a nursing shortage in the U.S.?

Questions loom on AstraZeneca cancer drug as safety concerns ebb

FDA's Woodcock to retire early next year

World's first CRISPR

focus

hotspot

leisure time

hotspot